

PIVOT-006

Are you interested in taking part in a Non-Muscle Invasive Bladder Cancer (NMIBC) clinical trial?

PIVOT-006 at-a-glance:

- Phase 3 NMIBC randomized trial
- Intermediate-Risk as defined by the AUA/SUO guidelines¹
- Cretostimogene grenadenorepvec
- Global Principal Investigator: Robert Svatek, M.D., MSCI

CG Oncology is now recruiting interested sites to the study

<https://clinicaltrials.gov/study/NCT06111235>

www.CGOnco.com

“NMIBC continues to be challenging because of frequent disease relapse and patients have limited available treatment options. Patients with Intermediate-Risk NMIBC have been underserved especially since the global BCG shortage. PIVOT-006 is a step in the right direction that aims to address this unmet need and help our patients. I hope that many other Urologists will be interested in this study”

Robert Svatek, M.D., MSCI
UT Health San Antonio

Please reach out to us for further information or to set up a time to discuss PIVOT-006 further.

Gigi Palomera:



615-549-4420

Gigi.Palomera@CGOnco.com

JoAnn Horn:

949-346-5997

JoAnn.Horn@CGOnco.com



CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Cretostimogene grenadenorepvec is currently being evaluated in a phase 3 study of monotherapy cretostimogene and in a phase 2 study in combination with pembrolizumab for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Cretostimogene grenadenorepvec was designed to directly kill cancer cells following tumor selective infection and replication while generating an anti-tumor immune response mediated by the production of granulocyte-macrophage colony-stimulating factor (GM-CSF).¹⁻³

Reference: **1.** Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. *J Urol.* 196:1021-1029. **2.** Laine, et al. Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy. *Molecular Therapy.* Vol. 10, No. 4, October 2004. **3.** Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. *World J Virol.* 2021 Sep 25;10(5):229-255. doi: 10.5501/wjv.v10.i5.229. PMID: 34631474; PMCID: PMC8474975. **4.** Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity.* 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012. PMID: 23890059.

CG Oncology is a trademark of CG Oncology Inc.
© 2023 CG Oncology Inc. All rights reserved. CGO-CRETO-2023HCP005